Effect of photobiomodulation on the viability of osteoblasts and fibroblasts submitted to alendronate sodium or zoledronic acid by Brozoski, Mariana Aparecida et al.
Clin Lab Res Den 2019: 1-8 ●  1
Oral Pathology
linical  and Laboratorial  
Research in Dentistry
in
1
Effect of photobiomodulation on the viability of osteoblasts 
and fibroblasts submitted to alendronate sodium or 
zoledronic acid: an in vitro study
• Mariana Aparecida Brozoski Oral and Maxillofacial Surgery Department, School of Dentistry, Universidade de São Paulo, São 
Paulo, SP, Brazil  • Natalia Caroline Aguiar Tartaroti Oral and Maxillofacial Surgery Department, School of Dentistry, Universidade 
de São Paulo, São Paulo, SP, Brazil  • Andreia Aparecida Traina Oral and Maxillofacial Surgery Department, School of Dentistry, 
Universidade de São Paulo, São Paulo, SP, Brazil  • Maria Cristina Zindel Deboni Oral and Maxillofacial Surgery Department, 
School of Dentistry, Universidade de São Paulo, São Paulo, SP, Brazil  • Marcia Martins Marques  Department of Restorative 
Dentistry, School of Dentistry, Universidade de São Paulo, São Paulo, SP, Brazil  • Maria da Graça Naclério Homem Oral and 
Maxillofacial Surgery Department, School of Dentistry, Universidade de São Paulo, São Paulo, SP Brazil 
 ABSTRACT |	 The	goal	of	this	study	is	to	evaluate	the	effect	of	photobiomodulation	therapy	(PBMT)	on	the	viability	of	osteoblasts	and	
cultured	fibroblasts	in	different	concentrations	of	alendronate	or	zoledronic	acid.	Two	cell	lines:	osteoblast-like	mouse	cells	
(OSTEO	1)	and	human	buccal	mucosa	fibroblast	(FMM1)	were	used.	Cells	were	submitted	to	different	concentrations	of	bis-
phosphonates	(1	μM,	10	μM,	and	100	μM	sodium	alendronate	and	3	μM,	5	μM	and	10	μM	zoledronic	acid)	for	24	hours.	Next,	
the	cultures	received	PBMT.	The	irradiations	were	applied	with	a	diode	laser	(InGaAIP,	660	nm,	30	mW,	spot	0.028	cm2)	in	
continuous,	punctual	and	contact	mode	at	two	energy	densities:	5	J/cm2	(4.5	s)	or	10	Jcm2	(9s)	with	6	hours-intervals.	Cell	
viability	was	determined	by	mitochondrial	activity	assay	(MTT)	24	h	after	the	last	irradiation.	The	data	were	compared	by	
the	one	way-	ANOVA,	complemented	by	the	Tukey’s	test	(p	<	0.05).	Sodium	alendronate	at	concentrations	of	100	μM	and	
10	μM	and	zoledronic	acid	at	10	μM	concentration	showed	higher	long-term	toxicity.	The	cellular	viability	of	the	PBMT	treated	
group	was	significantly	higher	than	that	of	the	negative	control	group.	The	same	occurred	with	the	osteoblasts	treated	with	
the	highest	concentrations	of	the	drug	(5	and	10	μM),	despite	not	reaching	the	cell	viability	of	the	positive	control	group,	it	
presented	greater	viability	than	the	negative	control	where	the	cells	were	not	irradiated.	In	the	groups	submitted	to	zoledronic	
acid,	positive	controls	presented	greater	cell	viability.	We	concluded	that	under	the	parameters	applied	in	this	study,	PBMT	
at	an	energy	density	of	5	J/cm2	was	able	to	revert	the	toxicity	of	sodium	alendronate	applied	at	the	higher	concentrations	in	
both	cell	types,	whereas	zoledronic	acid	toxicity,	regardless	of	its	concentrations,	was	not	influenced	by	PBMT.
 DESCRIPTORS |	 Osteonecrosis	of	the	Jaws;	Laser;	Alendronate;	Zoledronic	Acid.
 RESUMO | O efeito da fotobiomodulação na viabilidade de osteoblastos e fibroblastos submetidos ao alendronato de sódio ou ácido 
zoledrônico: um estudo in vitro •	O	objetivo	deste	estudo	é	avaliar	o	efeito	da	terapia	de	fotobiomodulação	(TFBM)	na	viabilidade	de	
osteoblastos	e	cultura	de	fibroblastos	em	diferentes	concentrações	de	alendronato	ou	ácido	zoledrônico.	Duas	linhagens	celulares	–	células	
de	camundongos	semelhantes	a	osteoblastos	(OSTEO	1)	e	fibroblastos	de	mucosa	bucal	humana	(FMM1)	–	foram	utilizadas.	As	células	
foram	submetidas	a	diferentes	concentrações	de	bisfosfonatos	(1	μM,	10	μM	e	100	μM	de	alendronato	de	sódio	e	3	μM,	5	μM	e	10	μM	de	ácido	
zoledrônico)	por	24	horas.	Em	seguida,	as	culturas	receberam	TFBM.	As	irradiações	foram	aplicadas	com	laser	de	diodo	(InGaAIP,	660	nm,	
30	mW,	spot	0,028	cm2)	em	modo	contínuo,	pontual	e	de	contato,	em	duas	densidades	de	energia:	5	J/cm2	(4,5	s)	ou	10	J/cm2	(9s)	com	
intervalos	de	6	horas.	A	viabilidade	celular	foi	determinada	pelo	ensaio	de	atividade	mitocondrial	(MTT)	24	h	após	a	última	irradiação.	Os	
dados	foram	comparados	pelo	ANOVA	One-Way,	complementado	pelo	teste	de	Tukey	(p	<	0,05).	O	alendronato	de	sódio	nas	concentrações	
de	100	μM	e	10	μM	e	o	ácido	zoledrônico	na	concentração	de	10	μM	apresentaram	maior	toxicidade	a	longo	prazo.	A	viabilidade	celular	do	
grupo	tratado	com	TFBM	foi	significativamente	maior	que	a	do	grupo	de	controle	negativo.	O	mesmo	ocorreu	com	os	osteoblastos	tratados	
com	as	maiores	concentrações	do	fármaco	(5	e	10	μM),	apesar	de	não	atingir	a	viabilidade	celular	do	grupo	de	controle	positivo,	apresentou	
maior	viabilidade	do	que	o	controle	negativo	no	qual	as	células	não	foram	irradiadas.	Nos	grupos	submetidos	ao	ácido	zoledrônico,	controles	
positivos	apresentaram	maior	viabilidade	celular.	Concluímos	que	sob	os	parâmetros	aplicados	neste	estudo,	a	TFBM,	com	uma	densidade	
de	energia	de	5	J/cm2,	foi	capaz	de	reverter	a	toxicidade	do	alendronato	sódico	aplicado	nas	concentrações	mais	altas	em	ambos	os	tipos	
celulares,	enquanto	a	toxicidade	do	ácido	zoledrônico,	independentemente	de	suas	concentrações,	foi	não	influenciada	pela	TFBM.
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INTRODUCTION
Bisphosphonates	(BFs)	are	drugs	used	since	1960	
for	the	treatment	of	diseases	of	bone	metabolism,	
such	as	bone	metastases	of	lung,	prostate	and	breast	
cancers;	multiple	myeloma;	Paget’s	disease;	among	
others.1,2	Nowadays	therapeutic	use,	of	that	drugs,	
has	 increased	primarily	 for	the	treatment	and	
prevention	of	osteoporosis	and	osteopenia.3	Despite	
their	therapeutic	efficacy,	these	treatments	with	BFs	
may	cause	undesirable	side	effects.	Among	them,	
osteonecrosis	of	the	jaws.	This	condition	was	initially	
known	as	Bisphosphonate-related	osteonecrosis	of	
the	jaw	(BRONJ).
Over	time	it	was	observed	that	BRONJ	side	
effect,	also	occurred	in	patients	submitted	to	other	
drugs	used	in	the	control	of	bone	metabolism	(new	
antiresorptive	and	antiangiogenic	drugs),	that	is,	
this	osteonecrosis	was	not	exclusively	the	result	
of	the	use	of	bisphosphonates.	For	this	reason,	in	
2014,	the	term	BRONJ	was	replaced	by	a	wider	one,	
namely	Medication-related	osteonecrosis	of	the	
jaw	(MRONJ).2
MRONJ	is	an	oral	lesion	that	is	difficult	to	resolve,	
it	imposes	treatments	with	the	use	of	antibiotics	
for	prolonged	periods,	surgical	debridement,	and	
even	resections	that	lead	the	patient	to	functional	
and	aesthetic	loss	with	a	significant	decrease	in	
quality	of	life.	The	pathophysiology	of	MRONJ	
has	not	yet	been	fully	elucidated.	It	is	well	known	
that	bisphosphonates	and	other	anti-resorptive	
medications	have	 two	 fundamental	biological	
effects,	namely:	inhibition	of	calcification	when	
administered	 in	high	doses,	and	 inhibition	of	
bone	resorption	related	to	anti-osteoclast	and	
antiangiogenic	activity.4-6
The	diagnosis	of	MRONJ	is	based	on	the	patient’s	
history	and	clinical	examination.	It	is	presented	
as	a	necrotic	bone	exposure,	ranging	from	a	few	
millimeters	to	larger	areas,	which	may	remain	
asymptomatic	for	weeks,	months,	or	years.	In	60%	
of	cases,	pain	may	be	present	when	inflammation	or	
infection	of	adjacent	tissues	occurs.7
Several	types	of	treatment	have	been	proposed	
for	MRONJ,	 including	 surgical	 debridement,	
ant ibiot ic 	 therapy, 2,3	 ozonotherapy 7,8	 and	
photobiomodulation	therapy	(PBMT).9-11	In	vivo	and	
in	vitro	studies	demonstrated	success	when	PBMT	
was	applied	in	different	parameters.12	However,	the	
underlying	mechanisms	involved	in	PBMT	effects	
in	 the	treatment	of	MRONJ	have	not	yet	been	
fully	elucidated.
In	the	search	for	these	mechanisms,	and	knowing	
that	the	repair	of	MRONJ	lesions	involves	cells	such	
as	osteoblasts	and	fibroblasts,	this	study	aimed	to	
evaluate	in	vitro	the	effect	of	PBMT,	when	applied	
with	different	parameters,	checking	the	viability	
of	 these	cells	under	 the	 inf luence	of	different	
concentrations	of	two	BFs:	alendronate	sodium	and	
zoledronic	acid.
METHODS
This	 study	was	 approved	 by	 the	Research	
Ethics	Committee	of	the	School	of	Dentistry	of	the	
University	of	São	Paulo	(FOUSP)	(Seem	#280.024).	
Two	cell	lines	were	used:	line	OSTEO	1	composed	of	
osteoblasts-like	cells	originating	from	parietal	bone	
periosteum	of	newborn	mouses,13,14	and	line	FMM1	
composed	of	human	buccal	mucosal	fibroblast	cells15 
kindly	donated	by	the	Basic	Research	Laboratory	of	
the	Department	of	Dentistry	of	FOUSP.
Cell culture
Cells	were	defrosted	and	cultivated	in	DMEM	
with	10%	fetal	bovine	serum	and	1%	antibiotic-
antimycotic	solution	(Sigma	Chemical,	St.	Louis,	MO,	
USA)	in	75	mm3	culture	flasks.	Daily	monitoring	of	
cell’s	growth	was	performed	using	inverted	phase	
microscopy	and	the	culture	medium	was	changed	
every	2	days,	according	to	the	cellular	metabolism.	
When	they	reached	70%	confluency	in	the	flask	they	
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were	trypsinized	and	subculture	into	4	48	well	plates	
(500	cells	per	well)	for	each	experimental	group.
Substances
Sodium	Alendronate	and	Zoledronic	Acid	were	
used.	Sodium	Alendronate	99%	(Formula	e	Ação,	São	
Paulo,	SP,	Brazil),	has	molecular	weight	of	325.12	g/
mol	and	chemical	formula	C4H12NNaO7P2.3H2O.	
Zoledronic	Acid	(Zometa®	–	Novartis	Pharma	
Stein	AG,	Stein,	Switzerland)	has	a	molecular	
weight	of	272.08	g/mol	and	chemical	 formula	
C5H8N2Na2O7P2	·	4H2O.
Photobiomodulation therapy (PBMT)
PBMT	was	applied	with	a	low	power	continuous	
diode	 laser	(Photon	Lase,	DMC	Equipamentos	
LTDA,	São	Carlos,	SP,	Brazil).	The	irradiations	were	
performed	in	the	following	parameters:	wavelength:	
660	nm	(active	medium	InGaAlP);	beam	area:	
0.028	cm2;	power:	30	mW;	power	density:	0.714	W/
cm2;	energy	densities:	5	J/cm2	or	10	J/cm2;	time	of	
irradiation	per	point:	4.5s	or	9s,	respectively;	energy	
per	point:	0.08	J	or	0.14	J,	respectively.	Irradiation	
was	performed	in	point	mode,	in	contact	at	a	single	
point	in	the	center	of	each	well	of	the	culture	plates.	
Two	irradiations	were	performed	with	a	6-hour	
interval.	The	plates	that	did	not	undergo	irradiation	
(controls)	received	the	same	experimental	treatments	
of	the	irradiated	plates	simulating	each	step	of	the	
PBMT,	but	with	the	equipment	turned	off.
Experimental Groups
Control: Cells	 (Osteo-1	or	FMM1)	grown	 in	
conventional	medium	(DMEM	with	10%	fetal	bovine	
serum	and	1%	antibiotic-antimycotic	solution	(Sigma	
Chemical).
Bisphosphonate:	Cells	(Osteo-1	or	FMM1)	grown	in	
conventional	conditioned	medium	with	Alendronate	
Sodium	(1	μM,	10	μM	or	100	μM)	or	Zoledronic	Acid	
(3	μM,	5	μM	or	10	μM).
PBMT 5J / cm2:	Cells	(Osteo-1	or	FMM1)	grown	
in	medium	containing	different	concentrations	of	
Alendronate	Sodium	(1	μM,	10	μM	or	100	μM)	or	
Zoledronic	Acid	(3	μM,	5	μM	or	10	μM)	and	irradiated	
with	energy	density	of	5	J/cm2.
PBMT 10 J/cm2: Cells	(Osteo-1	or	FMM1)	grown	
in	medium	containing	different	concentrations	of	
Alendronate	Sodium	(1	μM,	10	μM	or	100	μM)	or	
Zoledronic	Acid	3	μM,	5	μM	or	10	μM)	and	irradiated	
with	energy	density	of	10	J/cm2.
Cell viability
Cell	viability	analysis	was	based	on	the	MTT	
reduction	assay	(MTT	3-	(4,5-dimethylthiazol-2-
yl)	-2,5-diphenyltetrazolium	bromide).	Twenty-four	
hours	after	plating,	the	cells,	according	to	the	
experimental	groups,	received	the	conditioned	
media	or	not	(control).	Immediately	afterward	
they	were	 submitted	 to	 PBMT	 or	 not.	 Then,	
24	hours	after	the	last	irradiation	the	cultures	
were	 submitted	 to	 the	MTT	 reduction	 test.15 
This	test	measures	the	ability	of	mitochondrial	
enzymes	produced	by	metabolically	active	cells	
to	reduce	MTT	(Invitrogen,	Eugene,	OR,	USA)	
to	an	insoluble	formazan	salt,	which	after	being	
dissolved	in	DMSO	(Dimethyl	sulfoxide)	which	
was	then	measured	by	absorbance	at	562	nm	in	
a	spectrophotometer	(Amersham	Biosciences,	
Biochrom	Ltd.,	Cambridge,	England).
Statistical analysis
The	results	of	the	cell	viability	tests	obtained	in	
optical	density	were	transformed	into	percentage	
of	cell	viability.	The	mean	of	the	results	from	the	
control	group	was	considered	as	100%	viability.	
The	percentages	of	cell	viability	of	the	different	
experimental	 groups	 were	 compared	 by	 the	
ANOVA	–	1	criteria,	complemented	by	the	Tukey’s	
test.	The	statistical	program	BioEstat	version	5.0	
(p	<	0.05)	was	used.
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RESULTS
The	percentages	of	cell	viability	of	both	cell	lines	
(Osteo1	and	FMM1)	of	the	different	experimental	
groups	are	graphically	 illustrated	 in	Figure	 1	
namely:	PC-positive	control-	cultured	under	ideal	
conditions;	NC	negative	control-treated	with	sodium	
alendronate	and	no	further	treatment	and	those	who	
underwent	alendronate	sodium	and	PBMT	at	two	
power	densities	(5	and	10	J/cm2)	within	twenty-four	
hours	after	the	last	irradiation.
The	viability	of	the	positive	control	group	of	
Osteo	1	cells,	considered	to	be	100%	viability,	
was	significantly	higher	than	that	of	all	the	other	
groups	in	the	different	concentrations	of	sodium	
alendronate.	At	 the	 lowest	 concentration,	 the	
viability	percentages	of	all	experimental	groups	
were	similar.	At	higher	concentrations	(e.g.,	10	μm	
and	100	μm)	the	PBMT-treated	group	in	the	5	J/
cm2	parameter	showed	significantly	greater	cell	
viability	than	the	negative	control	group	within	
the	same	concentration	of	alendronate	sodium.	
The	cell	viability	of	the	10	J/cm2	treated	group	was	
intermediate,	like	the	negative	control	and	the	5	J/
cm2	group,	also	within	the	same	concentrations.
The	viability	of	the	FMM1	cell	control	group,	
which	was	100%	viability,	was	like	the	cellular	
viability	of	the	5	J/cm2	group	previously	submitted	
to	all	alendronate	sodium	concentrations	and	to	
the	10	J/cm2	group	only	in	the	concentration	lower	
(1æM).	At	the	highest	concentration	of	sodium	
alendronate	(100	μm),	the	group	treated	with	5	J/
cm2	presented	significantly	greater	viability	than	the	
negative	control	group	and	the	group	treated	with	
10	J/cm2	(p	<	0.05).	In	the	other	concentrations,	
the	viability	of	all	the	experimental	groups	was	
similar	(Figure	1).
Figure 1 | Graphical representation of the cell viability of osteoblasts OSTEO1 lineage – and FMM1 fibroblasts submitted to alendronate sodi-
um at concentrations 0 μm (Positive Control), 1 μm, 10 μm and 100 μm in the different experimental groups [Control-treatment and those treated 
by PBMT in the two densities of power (5 and 10 J/cm2)]. Different letters indicate significant differences between the experimental groups in the 
same concentration of sodium alendronate (p < 0.01). * Similar to the positive control.
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DISCUSSION
Drug-related	maxillary	osteonecrosis	is	strongly	
implicated	using	bisphosphonates,	especially	sodium	
alendronate	and	zoledronic	acid.16,17	PBMT	applied	
in	different	parameters	has	shown	beneficial	effects	
in	the	treatment	of	these	lesions,	but	little	is	known	
about	the	mechanisms	involved	in	this	effect.	It	is	
believed	that	the	effect	is	more	related	to	increased	
local	circulation	and	VEGF	secretion.	However,	
PBMT	has	also	been	identified	as	a	therapy	that	
prevents	cell	death.18	With	these	data,	the	present	
study	aimed	to	verify	a	possible	beneficial	effect	of	
photobiomodulation	therapy	on	the	maintenance	
of	the	viability	of	fibroblasts	and	osteoblasts,	cells	
involved	in	the	regeneration	of	tissues	affected	by	
MRONJ	lesions.	The	viability	of	these	cells	submitted	
to	different	concentrations	of	sodium	alendronate	
or	zoledronic	acid	was	evaluated.	It	was	found	that	
zoledronic	acid	at	the	different	concentrations	tested	
was	highly	toxic	and	that	PBMT	was	not	able	to	
reverse	this	effect.	PBMT	exerted	a	beneficial	effect	
on	the	fibroblasts	submitted	to	the	parameter	of	lower	
energy	density	(5	J/cm2),	which	was	able	to	maintain	
cellular	viability	levels	like	that	of	the	positive	control	
group	cultured	under	the	best	conditions.
Since	the	first	publication	in	2003	reporting	
bisphosphonate-induced	osteonecrosis16	the	subject	
has	gained	repercussion	in	the	scientific	community,	
Figure 2 | Graphical illustrates the cell viability percentages of both cell types (Osteo1 and FMM1) of the different experimental groups, 
namely: PC-positive control- cultured under optimal conditions; NC negative control-treated with zoledronic acid and no further treatment and 
those who underwent zoledronic acid and PBMT at two power densities (5 and 10 J/cm2) within twenty-four hours after the last irradiation.
The	viability	of	the	positive	control	group	of	
both	cell	types	(Osteo1	and	FMM1),	considered	
to	be	100%	viability,	was	significantly	higher	
than	that	of	all	the	other	groups	in	the	different	
concentrations	of	zoledronic	acid	(p	<	0.01).	There	
were	no	differences	between	the	viabilities	of	the	
other	groups	in	all	concentrations	of	zoledronic	acid	
tested	(Figure	2).
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but	countless	questions	remain	unanswered.	The	
exact	mechanism	of	how	this	class	of	medication	
works	in	the	development	of	osteonecrosis	is	not	yet	
established.	It	is	known	that	the	type	of	medication,	
the	time	of	use	and	the	route	of	administration	are	
factors	that	influence	MRONJ.1-7	Some	authors	cite	
that	the	cytotoxicity	of	the	drug	is	one	of	the	factors	
for	the	development	of	osteonecrosis.5,6	Others	
point	out	that	the	local	microbiota	is	a	determining	
factor	for	lesion	appearance.16,17,19	The	association	
between	altered	bone	metabolism,	cytotoxicity,	
decreased	angiogenesis,	microbiota	and	the	constant	
microtrauma	affecting	the	oral	cavity	are	the	most	
cited	factors	in	the	pathophysiology	of	MRONJ.4
There	is	no	consensus	in	the	literature	regarding	
treatment	protocols	for	MRONJ.	Several	types	of	
conducts	are	employed,	from	clinical	follow-up	and	
antibiotic	therapy	to	large	resections	of	the	maxilla	
and	mandible.3,17,9	The	PBMT	applied	both	to	the	
wavelength	in	the	red	and	infrared	spectrum	has	been	
applied	with	positive	results	in	cases	of	MRONJ.9-11
The	use	of	Nd:	YAG	laser	for	the	treatment	of	
MRONJ	for	PBMT,	associated	or	not	to	the	surgical	
procedure,	presented	good	clinical	results.11	MRONJ	
lesions	treated	by	the	combination	of	PBMT	with	
drug	treatment	and	surgery	have	a	higher	rate	
of	 injury	repair	 than	when	 lesions	are	 treated	
solely	by	medications	and	surgery	probably	by	
increased	angiogenesis.9
Previous	studies	have	already	shown	that	PBMT	
is	able	to	compensate	for	the	cytotoxic	effect	of	
substances	applied	on	cells	of	oral	tissues,	such	
as	human	buccal	mucosa	fibroblasts	submitted	
to	dental	bleaching	gels,20	as	well	as	stem	cells	
from	human	dental	pulps	submitted	to	dental	
adhesives.21	Moreover,	in	translational	studies	in	
rats,	we	observed	that	PBMT	was	able	to	prevent	
cell	death.18	Based	on	these	results	we	hypothesized	
that	the	beneficial	effects	of	PBMT	in	the	treatment	
of	MRONJ	lesions	perhaps	might	be	related	to	the	
control	of	the	cytotoxic	effect	of	ant	reabsorbing	
drugs	on	 the	 cells	 of	 the	oral	 tissues	 such	as	
fibroblasts	and	osteoblasts.	For	this	reason,	we	
submitted	these	cell	types	to	different	concentrations	
of	two	of	the	most	BFs	related	to	the	development	
of	MRONJ,	sodium	alendronate	and	zoledronic	acid	
and	applied	PBMT	to	verify	whether	this	therapy	
could	positively	influence	the	ability	of	these	cells	
to	survive	the	toxic	effects	of	BFs.
The	cytotoxicity	of	bisphosphonates	has	been	
demonstrated	by	different	in	vitro	studies,	where	the	
concentration	of	the	medication,	the	type	of	the	cell,	
and	the	time	of	contact	with	the	drug	influence	the	
toxic	effect	on	the	cells.22-24	In	this	study,	we	used	high	
drug	concentrations	(Alendronate	sodium	–	100	μm,	
10	μm	–	and	zoledronic	acid,	5	μm,	and	10	μm)	to	
submitted	cells	to	the	highest	toxicity	challenge.
Clinical	studies	use	 laser	 light	with	diverse	
parameters,	using	wavelengths	in	the	spectrum	from	
red	to	infrared	was	successfully	for	the	treatment	of	
MRONJ.9,25,26	It	is	known	that	the	parameters	used	
for	PBMT	influence	the	results	obtained.27	In	the	
present	work,	the	parameters	applied	were	those	
determined	in	previous	studies	that	observed	that	
lower	energy	density	was	more	effective	to	stimulate	
cells	in	culture.27-30
The	results	of	the	present	study	demonstrated	
that	zoledronic	acid	even	at	the	highest	concentration	
used	(10	μM)	showed	higher	long-term	toxicity,	as	did	
sodium	alendronate	at	concentrations	of	100	μM	and	
10	μM.	Sodium	alendronate	at	1μM	concentration	
was	not	cytotoxic	for	the	cells	used,	and	therefore	
PBMT	did	not	alter	the	cell	viability	of	the	cells	of	
this	experimental	group	since	the	cells	had	metabolic	
alteration	neither	by	nutritional	deficit	nor	by	the	
cytotoxicity	of	the	drug	to	which	were	exposed.	In	
fact,	Almeida	Lopes	et	al.	in	200130	have	already	
observed	that	nutritional	deficiency	in	cultured	cells	
was	critical	for	cells	to	respond	to	PBMT.
We	 observed	 that	 in	 the	 parameters	 and	
concentrations	used	PBMT	was	able	to	partially	
reverse	the	cytotoxicity	of	alendronate,	but	not	
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zoledronic	acid.	On	the	other	hand,	PBMT	has	been	
shown	to	modulate	cellular	metabolism.	Some	in	
vitro	studies	have	demonstrated	that	PBMT	can	
accelerate	the	growth	of	fibroblasts,	osteoblasts	
and	endothelial	cells.27-33	It	is	known	that	PBMT	
presents	numerous	benefits	such	as	modulation	
of	 the	 inf lammatory	process,	 acceleration	of	
t issue	 repair,	 and	 favors	 angiogenesis	 and	
promotes	analgesia.31	Endothelial	cells	exhibited	
their	 increased	proliferation	when	 subjected	
to	PBMT23	induces	secretion	of	growth	factors,	
such	as	fibroblast	growth	factor	(FGF).32	PBMT	
also	 positively	 affects	 the	 proliferation	 and	
differentiation	of	human	stem	cells.33-35 These 
factors	are	important	for	PBMT	to	be	considered	
promising	for	the	treatment	of	MRONJ.
CONCLUSIONS
This	 study	has	 shown	 that	PBMT	could	be	
a	 relevant	 adjunctive	 therapy	 for	 improving	
healing	after	surgeries	done	 in	patients	under	
alendronate	therapy.
Finally,	new	PBMT	protocols	could	tested	in	
future	in	order	to	find	effective	parameters	to	be	
applied	in	patients	under	BFs	treatment	or	to	treat	
MRONJ	lesions.
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